GP2013
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Indolent B-cell Non-Hodgkin's Lymphoma
Conditions
Indolent B-cell Non-Hodgkin's Lymphoma
Trial Timeline
May 1, 2013 โ Aug 1, 2014
NCT ID
NCT01933516About GP2013
GP2013 is a phase 1 stage product being developed by Novartis for Indolent B-cell Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01933516. Target conditions include Indolent B-cell Non-Hodgkin's Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01933516 | Phase 1 | Completed |
Competing Products
15 competing products in Indolent B-cell Non-Hodgkin's Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Linperlisib ๏ผ Rituximab | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| Ibrutinib + GA 101 | Roche | Phase 2 | 52 |
| Obinutuzumab + Bendamustine | Roche | Phase 2 | 52 |
| Placebo + Rituximab + Idelalisib | Gilead Sciences | Phase 3 | 76 |
| Idelalisib | Gilead Sciences | Phase 1/2 | 40 |
| Idelalisib + Rituximab + Bendamustine + Placebo | Gilead Sciences | Phase 3 | 76 |
| Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + Lenalidomide | Gilead Sciences | Phase 1 | 32 |
| IBI376 | Innovent Biologics | Phase 2 | 51 |
| Copanlisib + Nivolumab + Rituximab | Bristol Myers Squibb | Phase 1 | 32 |
| SAR245409 | Sanofi | Phase 1 | 32 |
| Copanlisib (BAY80-6946) | Bayer | Pre-clinical | 20 |
| Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2 | Lundbeck | Phase 3 | 74 |
| Bezuclastinib | Cogent Biosciences | Pre-clinical | 20 |